Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone702-835-6300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$109.33 million
Profitability
Miscellaneous
Employees235
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.04. Spectrum Pharmaceuticals had a negative return on equity of 37.72% and a negative net margin of 109.76%. During the same quarter last year, the firm posted ($0.15) EPS. View Spectrum Pharmaceuticals' Earnings History.
When is Spectrum Pharmaceuticals' next earnings date?
What price target have analysts set for SPPI?
5 equities research analysts have issued 1-year price targets for Spectrum Pharmaceuticals' shares. Their predictions range from $19.00 to $40.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $24.00 in the next year. This suggests a possible upside of 209.3% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.
What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.
What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "With the sale of marketed products, Spectrum Pharma lost a steady stream of revenues. Although the BLA for Rolonits was submitted last year, it was withdrawn in March 2019. Spectrum has faced regulatory setbacks in the past including rejection of regulatory application for Qapzola seeking approval for bladder cancer in the United States. Additional regulatory/development setbacks, especially related to Rolontis, could affect the stock. Spectrum’s shares have underperformed the industry in the past year. However, development of poziotinib is progressing well including in the phase II pivotal study in second-line lung cancer. Moreover, sale of its marketed products will help Spectrum to focus on and support the development of its pipeline candidates. Loss estimates remained stable ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (5/1/2019)
- 2. HC Wainwright analysts commented, "Our $40 price target is derived from an NPV of Spectrum’s proprietary pipeline, a sum-of-the-parts analysis based on the P/E value of its current commercial business, plus cash. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 3x. We value the pipeline at $12.19 per share (x3= $36.57), the current commercial business at $1.48 per share and YE18 estimated fully diluted net cash at $1.49 per share." (1/10/2019)
Has Spectrum Pharmaceuticals been receiving favorable news coverage?
News stories about SPPI stock have been trending negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days.
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Amneal Pharmaceuticals (AMRX), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO) and Uniqure (QURE).
What other stocks do shareholders of Spectrum Pharmaceuticals own?
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
- Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
- Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
- Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
- Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
Who are Spectrum Pharmaceuticals' major shareholders?
Spectrum Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.97%), Primecap Management Co. CA (9.88%), ArrowMark Colorado Holdings LLC (3.15%), Macquarie Group Ltd. (2.46%), FMR LLC (1.91%) and Renaissance Technologies LLC (1.51%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.
Which institutional investors are selling Spectrum Pharmaceuticals stock?
SPPI stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Voya Investment Management LLC, Morgan Stanley, Ashford Capital Management Inc., Goldman Sachs Group Inc., DekaBank Deutsche Girozentrale, Fosun International Ltd and ClariVest Asset Management LLC. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.
Which institutional investors are buying Spectrum Pharmaceuticals stock?
SPPI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sio Capital Management LLC, ArrowMark Colorado Holdings LLC, Macquarie Group Ltd., BlackRock Inc., SG Americas Securities LLC, Geode Capital Management LLC and AQR Capital Management LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.
How do I buy shares of Spectrum Pharmaceuticals?
Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectrum Pharmaceuticals' stock price today?
One share of SPPI stock can currently be purchased for approximately $7.76.
How big of a company is Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals has a market capitalization of $868.83 million and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.
What is Spectrum Pharmaceuticals' official website?
How can I contact Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]
MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
